Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2021-04-22
Target enrollment:
Participant gender:
Summary
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study
to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following
twice-daily applications to target areas of patients with moderate or severe atopic
dermatitis.